O'Shaughnessy Asset Management’s CDK Global, Inc. CDK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-161
Closed -$7K 2755
2021
Q3
$7K Sell
161
-8
-5% -$360 ﹤0.01% 2272
2021
Q2
$8K Sell
169
-15
-8% -$794 ﹤0.01% 2063
2021
Q1
$10K Buy
184
+27
+17% +$1.4K ﹤0.01% 1794
2020
Q4
$8K Buy
157
+55
+54% +$2.61K ﹤0.01% 1602
2020
Q3
$4K Buy
102
+50
+96% +$2.22K ﹤0.01% 1543
2020
Q2
$2K Buy
+52
New +$2K ﹤0.01% 1542
2019
Q3
Sell
-490,026
Closed -$24.2M 1303
2019
Q2
$24.2M Sell
490,026
-183,158
-27% -$9.81M 0.57% 55
2019
Q1
$39.5M Sell
673,184
-23,321
-3% -$1.27M 0.94% 34
2018
Q4
$33.4M Sell
696,505
-30,987
-4% -$1.63M 0.84% 39
2018
Q3
$45.4M Buy
727,492
+49,570
+7% +$3.14M 0.93% 36
2018
Q2
$44M Buy
677,922
+31,892
+5% +$2.06M 0.93% 31
2018
Q1
$40.9M Buy
646,030
+291,925
+82% +$20.4M 0.9% 35
2017
Q4
$25.2M Sell
354,105
-19,346
-5% -$1.3M 0.59% 44
2017
Q3
$23.6M Buy
373,451
+122,254
+49% +$7.7M 0.55% 50
2017
Q2
$15.6M Buy
+251,197
New +$15.8M 0.37% 59

Other funds holding CDK

O'Shaughnessy Asset Management's CDK Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of CDK Global, Inc. (CDK) in Q4 2021, closing a stake of 161 shares — an estimated $7K sold.

O'Shaughnessy Asset Management first reported a position in CDK in Q2 2017 and held it in 15 quarters. The position peaked at $45.4M in Q3 2018. 448 funds tracked by Wall St. Rank hold CDK as of Q4 2021.

  • O'Shaughnessy Asset Management reported no remaining CDK Global, Inc. position as of Q4 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 161 CDK Global, Inc. shares in Q4 2021, an estimated $7K.
  • O'Shaughnessy Asset Management first reported a position in CDK Global, Inc. in Q2 2017 and held it in 15 quarters.
  • O'Shaughnessy Asset Management's CDK Global, Inc. position peaked at $45.4M in Q3 2018.
  • 448 funds tracked by Wall St. Rank held CDK Global, Inc. as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.